BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH
170 results:

  • 1. [Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia].
    Gao HL; Hao Y; Chen WM; Li LD; Wang X; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):906-910. PubMed ID: 38185519
    [No Abstract]    [Full Text] [Related]  

  • 2. The association of environmental factors with neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia (ALL).
    Nigro SE; Hall LP; Harman J; Willard VW; Conklin HM; Pui CH; Jeha S; Jacola LM
    Support Care Cancer; 2023 Dec; 32(1):1. PubMed ID: 38047975
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
    Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Physical activity in recurrent colon cancer: Cancer and leukemia Group B/SWOG 80702 (Alliance).
    Brown JC; Ma C; Shi Q; Zemla T; Couture F; Kuebler P; Kumar P; Tan B; Krishnamurthi S; Chang V; Goldberg RM; Venook AP; Blanke CD; O'Reilly EM; Shields AF; Meyerhardt JA
    Cancer; 2023 Dec; 129(23):3724-3734. PubMed ID: 37651160
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
    Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
    Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
    Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
    Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database.
    Pastori D; Marang A; Bisson A; Herbert J; Lip GYH; Fauchier L
    J Am Heart Assoc; 2022 Dec; 11(23):e026388. PubMed ID: 36444864
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
    de Botton S; Montesinos P; Schuh AC; Papayannidis C; Vyas P; Wei AH; Ommen H; Semochkin S; Kim HJ; Larson RA; Koprivnikar J; Frankfurt O; Thol F; Chromik J; Byrne J; Pigneux A; Thomas X; Salamero O; Vidriales MB; Doronin V; Döhner H; Fathi AT; Laille E; Yu X; Hasan M; Martin-Regueira P; DiNardo CD
    Blood; 2023 Jan; 141(2):156-167. PubMed ID: 35714312
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Association of antibiotic-consumption patterns with the prevalence of hematological malignancies in European countries.
    Ternák G; Berényi K; Németh B; Szenczi Á; Márovics G; Kiss I
    Sci Rep; 2022 May; 12(1):7821. PubMed ID: 35550556
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
    Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
    Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study.
    Jensen KS; Klug Albertsen B; Schrøder H; Zalounina Falborg A; Schmiegelow K; Rosthøj S; Callesen MT; Vedsted P
    BMJ Open; 2021 Nov; 11(11):e049847. PubMed ID: 34810184
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
    Bonafede M; Anaissie E; Evans K; Itzler R
    BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
    Yamauchi T; Yoshida C; Usuki K; Takada S; Matsumura I; Dobashi N; Miyazaki Y; Miyamoto T; Iida H; Asou N; Kuroda J; Ichikawa S; Komatsu N; Mendes W; Honda H; Okubo S; Kurokawa M; Jiang Q; Wei A; Ishizawa K
    Jpn J Clin Oncol; 2021 Aug; 51(9):1372-1382. PubMed ID: 34322703
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
    Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
    Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid leukemia: A Pilot Study.
    Hyland KA; Nelson AM; Eisel SL; Hoogland AI; Ibarz-Pinilla J; Sweet K; Jacobsen PB; Knoop H; Jim HSL
    Ann Behav Med; 2022 Feb; 56(2):137-145. PubMed ID: 33991085
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Severe hypercalcemia in a patient with chronic lymphocytic leukemia and non-small cell lung carcinoma: A case report.
    Shacham EC; Marshak DC; Brikman S; Dori G; Ishay A
    Medicine (Baltimore); 2021 Apr; 100(14):e24982. PubMed ID: 33832072
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The factors influencing clinical outcomes after leukapheresis in acute leukaemia.
    Lee H; Park S; Yoon JH; Cho BS; Kim HJ; Lee S; Kim DW; Chung NG; Cho B; Kim KB; Yoo J; Jekarl DW; Chae H; Lim J; Kim M; Oh EJ; Kim Y
    Sci Rep; 2021 Mar; 11(1):6426. PubMed ID: 33742034
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome.
    Marlow EC; Ducore J; Kwan ML; Cheng SY; Bowles EJA; Greenlee RT; Pole JD; Rahm AK; Stout NK; Weinmann S; Smith-Bindman R; Miglioretti DL
    J Pediatr; 2021 Jul; 234():172-180.e3. PubMed ID: 33684394
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
    Roerden M; Märklin M; Salih HR; Bethge WA; Klein R; Rammensee HG; Nelde A; Walz JS
    Leuk Lymphoma; 2021 Aug; 62(8):1907-1919. PubMed ID: 33648413
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study.
    Pastori D; Marang A; Bisson A; Menichelli D; Herbert J; Lip GYH; Fauchier L
    Cancer; 2021 Jun; 127(12):2122-2129. PubMed ID: 33631041
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 9.